Printer Friendly

LEXINGTON PHARMACEUTICAL COMPANY PAYS $25,000 IN SETTLEMENT OF GOVERNMENT'S CHARGES UNDER COMPREHENSIVE DRUG ABUSE PREVENTION ACT

 BOSTON, April 16 /PRNewswire/ -- United States Attorney A. John Pappalardo today announced that Interneuron Pharmaceuticals, Inc., a Lexington, Mass. company engaged in pharmaceutical research, has paid $25,000.00 in settlement of the government's civil claims that the company failed to comply with the record-keeping requirements of the Comprehensive Drug Abuse Prevention and Control Act of 1970.
 More particularly, the government claimed that during the period Jan. 1, 1991 to Feb. 1, 1993, Interneuron failed to maintain required records of controlled substances ordered and received, failed to maintain required inventories and failed to maintain complete and accurate records of each substance received, sold, delivered or otherwise disposed of by Interneuron. As part of the settlement, Interneuron denied the allegations of the United States.
 This settlement is the result of an investigation conducted by the United States Drug Enforcement Administration. The case is being handled by Assistant U.S. Attorney David Abelman of Pappalardo's Civil Division.
 -0- 4/16/93
 /CONTACT: Press Officer of the U.S. Attorney's Office, 617-223-9445/


CO: ST: Massachusetts IN: SU:

DJ -- NE016 -- 6987 04/16/93 17:58 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 16, 1993
Words:183
Previous Article:RAYTHEON EXPANDS RAYTHEON ENGINEERS & CONSTRUCTORS BUSINESS SEGMENT
Next Article:PHAR-MOR COMPLETES REVISED BUSINESS PLAN; STORE CONSOLIDATION, COST REDUCTIONS AND INVESTMENT IN CONTINUING STORES TO REINFORCE POSITION
Topics:


Related Articles
FLORIDA COMPANY SIGNS CONSENT DECREE IN SCHERING TRADEMARK SUIT
$700,000 CIVIL PENALTY PAID BY DUNNINGTON RX SERVICES TO SETTLE FEDERAL CHARGES, U.S. ATTORNEY ANNOUNCES
THE NATIONAL PHARMACEUTICAL COUNCIL AND THE WHITE HOUSE OFFICE OF NATIONAL DRUG CONTROL POLICY ANNOUNCE PREVENTION EDUCATION PARTNERSHIP
AstraZeneca fined $355 million as U.S. cracks down on medicare fraud.
Lilly Resolves Investigation of Its Evista Marketing and Promotional Practices.
Bristol-Myers Squibb Pleads Guilty to Lying to the Federal Government About Deal Involving Blood-Thinning Drug.
Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters